精彩内容近日,鲁南厚普制药的感冒中成药荆防合剂再有新适应症获批临床。米内网数据显示,2025年前三季度中国三大终端六大市场感冒中成药销售额超过130亿元。院内市场中,以岭药业稳坐龙头,9个独家品种上榜TOP20产品;零售药店中,20亿大品种领跑,华润三九霸榜。17款感冒中药新药上市可期,涉及康缘药业、天士力等企业。超200亿市场承压!17款中药新药上市可期感冒是生活中的常见病、多发病,秋冬季节更是...
Source Link精彩内容近日,鲁南厚普制药的感冒中成药荆防合剂再有新适应症获批临床。米内网数据显示,2025年前三季度中国三大终端六大市场感冒中成药销售额超过130亿元。院内市场中,以岭药业稳坐龙头,9个独家品种上榜TOP20产品;零售药店中,20亿大品种领跑,华润三九霸榜。17款感冒中药新药上市可期,涉及康缘药业、天士力等企业。超200亿市场承压!17款中药新药上市可期感冒是生活中的常见病、多发病,秋冬季节更是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.